Peter AG Sandercock

54.3k citations
389 papers · 39.7k · 19 hit papers · h-index 96

Impact in

Papers in

Peter AG Sandercock

381 papers receiving 37.3k citations

Peter AG Sandercock's Hit Papers

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial 2022 · 282 citations
2820+11+22Years since publication50010001.5k2.0k2.5k

Peers

Peter AG Sandercock
Comparison fields: 5 of 202
  • Internal Medicine 2.4k
  • Rehabilitation 3.7k
  • Neurology 7.6k
  • Epidemiology 14.6k
  • Cardiology and Cardiovascular Medicine 6.0k
Replace S. Claiborne Johnston with:
S. Claiborne Johnston United States
Lee H. Schwamm United States
Larry B. Goldstein United States
Edward C. Jauch United States
David Tirschwell United States
Kennedy R. Lees United Kingdom
Karen L. Furie United States
Bo Norrving Sweden
Bruce I Ovbiagele United States
Joseph Broderick United States
Peter AG Sandercock relative to S. Claiborne Johnston United States S. Claiborne Johnston's profile →
Citations per field
00.5×1.5×
S. Claiborne Johnston · 1×
Citations per year

Countries citing papers authored by Peter AG Sandercock

Since Specialization
Citations

This map shows the geographic impact of Peter AG Sandercock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter AG Sandercock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter AG Sandercock more than expected).

Fields of papers citing papers by Peter AG Sandercock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter AG Sandercock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter AG Sandercock. The network helps show where Peter AG Sandercock may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter AG Sandercock, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter AG Sandercock Line = papers co-authored together Peter AG Sandercock links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 389 papers — load more, or switch the sort, to bring in the rest.

#Work
1
COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
Hit paper breakdown →
19942867
2
Classification and natural history of clinically identifiable subtypes of cerebral infarction
Hit paper breakdown →
19912785
3
International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion
Hit paper breakdown →
20052197
4
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
Hit paper breakdown →
20142076
5
Interpretation of the evidence for the efficacy and safety of statin therapy
Hit paper breakdown →
20161442
6
Stroke in China: advances and challenges in epidemiology, prevention, and management
Hit paper breakdown →
20191212
7
Effect of intravenous corticosteroids on death within 14 days in 10 008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial
Hit paper breakdown →
2004837
8
Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
Hit paper breakdown →
2012804
9
Blood Pressure and Clinical Outcomes in the International Stroke Trial
Hit paper breakdown →
2002776
10
ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION
Hit paper breakdown →
1992757
11
A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project--1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage.
Hit paper breakdown →
1990676
12
Comparison of treatment effects between animal experiments and clinical trials: systematic review
Hit paper breakdown →
2006650
13
Interobserver agreement for the assessment of handicap in stroke patients.
Hit paper breakdown →
1989599
14
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
Hit paper breakdown →
2013571
15
Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project.
Hit paper breakdown →
1993487
16 2007462
17 2000461
18 1994460
19 1988408
20
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Hit paper breakdown →
2021403

About Peter AG Sandercock

Peter AG Sandercock is a scholar working on Epidemiology, Internal Medicine, Neurology, Rehabilitation and Pulmonary and Respiratory Medicine, having authored 389 papers that have together received 39.7k indexed citations. Recurring topics across this work include Acute Ischemic Stroke Management (211 papers), Cerebrovascular and Carotid Artery Diseases (80 papers), Venous Thromboembolism Diagnosis and Management (40 papers), Stroke Rehabilitation and Recovery (40 papers), Traumatic Brain Injury and Neurovascular Disturbances (24 papers), Intracerebral and Subarachnoid Hemorrhage Research (22 papers), Antiplatelet Therapy and Cardiovascular Diseases (21 papers) and Meta-analysis and systematic reviews (19 papers). The work is most often cited by research in Internal Medicine (2.4k citations), Rehabilitation (3.7k citations), Neurology (7.6k citations), Epidemiology (14.6k citations) and Cardiology and Cardiovascular Medicine (6.0k citations). Peter AG Sandercock has collaborated with scholars based in United Kingdom, Australia and United States. Frequent co-authors include Martin S. Dennis, John Bamford, John Burn, C P Warlow, Joanna Marguerite Wardlaw, Charles P Warlow, Charles Warlow, Richard I. Lindley, Andrew Molyneux and William N. Whiteley. Their work appears in journals such as Stroke, The Lancet, International Journal of Stroke, Cerebrovascular Diseases and Journal of Neurology Neurosurgery & Psychiatry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact